Regulating cytokine function enhances safety and activity of genetic cancer therapies

Molecular Therapy

Volumn 21, Issue 1, 2013, Pages 167-174

  Chen, Hannah ^a   Sampath, Padma ^a   Hou, Weizhou ^a   Thorne, Stephen H ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; ONCOLYTIC VIRUS; RANTES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER THERAPY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FEMALE; GENE EXPRESSION; IMMUNOREACTIVITY; IN VITRO STUDY; INTERLEUKIN 2 GENE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS REPLICATION;

EID: 84871905027     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.225     Document Type: Article

References (28)

1. DeFrancesco, L (2010). Landmark approval for Dendreon's cancer vaccine. NatBiotechnol 28: 531-532.
2. Schmidt, C (2011). Amgen spikes interest in live virus vaccines for hard-to-treatcancers. Nat Biotechnol 29: 295-296.
3. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al.(2008). Use of a targeted oncolytic poxvirus, JX-594, in patients withrefractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9:533-542.
4. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011).Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus inhumans. Nature 477: 99-102.
5. Kaufman, HL, Kim, DW, DeRaffele, G, Mitcham, J, Coffin, RS and Kim-Schulze, S(2010). Local and distant immunity induced by intralesional vaccination with anoncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.Ann Surg Oncol 17: 718-730.
6. Kirn, DH (2011). Redemption for the field of oncolytic virotherapy. Mol Ther 19:627-628.
7. Harrington, KJ, Vile, RG, Melcher, A, Chester, J and Pandha, HS (2010).Clinical trials with oncolytic reovirus: moving beyond phase I intocombinations with standard therapeutics. Cytokine Growth Factor Rev 21:91-98.
8. Willmon, CL, Saloura, V, Fridlender, ZG, Wongthida, P, Diaz, RM, Thompson,J et al. (2009). Expression of IFN-beta enhances both efficacy and safety ofoncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 69:7713-7720.
9. Kirn, DH, Wang, Y, Le Boeuf, F, Bell, J and Thorne, SH (2007). Targeting of interferonbetato produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4:e353.
10. Banaszynski, LA, Sellmyer, MA, Contag, CH, Wandless, TJ and Thorne, SH (2008).Chemical control of protein stability and function in living mice. Nat Med 14:1123-1127.
11. Saloura, V, Wang, LC, Fridlender, ZG, Sun, J, Cheng, G, Kapoor, V etal. (2010). Evaluation of an attenuated vesicular stomatitis virus vectorexpressing interferon-beta for use in malignant pleural mesothelioma:heterogeneity in interferon responsiveness defines potential efficacy. Hum GeneTher 21: 51-64.
12. Lei, N, Shen, FB, Chang, JH, Wang, L, Li, H, Yang, C et al. (2009). An oncolyticadenovirus expressing granulocyte macrophage colony-stimulating factor showsimproved specificity and efficacy for treating human solid tumors. Cancer Gene Ther16: 33-43.
13. Allen, C, Paraskevakou, G, Iankov, I, Giannini, C, Schroeder, M, Sarkaria, J etal. (2008). Interleukin-13 displaying retargeted oncolytic measles virus strainshave significant activity against gliomas with improved specificity. Mol Ther 16:1556-1564.
14. Banaszynski, LA, Chen, LC, Maynard-Smith, LA, Ooi, AG and Wandless, TJ (2006). Arapid, reversible, and tunable method to regulate protein function in living cells usingsynthetic small molecules. Cell 126: 995-1004. (Pubitemid 44310772)
15. Banaszynski, LA and Wandless, TJ (2006). Conditional control of protein function.Chem Biol 13: 11-21. (Pubitemid 43099920)
16. Dutcher, J (2002). Current status of interleukin-2 therapy for metastatic renal cellcarcinoma and metastatic melanoma. Oncology (Williston Park, NY) 16(11 Suppl 13):4-10.
17. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemiccancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinaseand vaccinia growth factor genes. Cancer Res 61: 8751-8757. (Pubitemid 34013887)
18. Thorne, SH, Hwang, TH, O'Gorman, WE, Bartlett, DL, Sei, S, Kanji, F et al. (2007).Rational strain selection and engineering creates a broad-spectrum, systemicallyeffective oncolytic poxvirus, JX-963. J Clin Invest 117: 3350-3358. (Pubitemid 350096991)
19. Rojas, JJ and Thorne, SH (2012). Theranostic potential of oncolytic vaccinia virus.Theranostics 2: 363-373.
20. Davison, AJ and Moss, B (1989). Structure of vaccinia virus late promoters. J Mol Biol210: 771-784. (Pubitemid 20049083)
21. Araki, K, Turner, AP, Shaffer, VO, Gangappa, S, Keller, SA, Bachmann, MF etal. (2009). mTOR regulates memory CD8 T-cell differentiation. Nature 460:108-112.
22. Miller, JD, van der Most, RG, Akondy, RS, Glidewell, JT, Albott, S, Masopust, D et al.(2008). Human effector and memory CD8+ T cell responses to smallpox and yellowfever vaccines. Immunity 28: 710-722.
23. Drillien, R, Spehner, D, Bohbot, A and Hanau, D (2000). Vaccinia virus-relatedevents and phenotypic changes after infection of dendritic cells derived from humanmonocytes. Virology 268: 471-481. (Pubitemid 30159996)
24. Mikloska, Z, Bosnjak, L and Cunningham, AL (2001). Immature monocyte-deriveddendritic cells are productively infected with herpes simplex virus type 1. J Virol 75:5958-5964. (Pubitemid 32553126)
25. Hu, JC, Coffin, RS, Davis, CJ, Graham, NJ, Groves, N, Guest, PJ et al. (2006). A phaseI study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virusexpressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12:6737-6747. (Pubitemid 44876843)
26. Maynard-Smith, LA, Chen, LC, Banaszynski, LA, Ooi, AG and Wandless, TJ (2007). Adirected approach for engineering conditional protein stability using biologically silentsmall molecules. J Biol Chem 282: 24866-24872. (Pubitemid 47347507)
27. Iuliucci, JD, Oliver, SD, Morley, S, Ward, C, Ward, J, Dalgarno, D et al. (2001).Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, inhealthy volunteers. J Clin Pharmacol 41: 870-879. (Pubitemid 32692098)
28. Chakrabarti, S, Sisler, JR and Moss, B (1997). Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 23: 1094-1097. (Pubitemid 27523268)